Regulatory News:
Cellectis SA (Paris:ALCLS) (Alternext: ALCLS.PA) announces that it has
entered into an exclusive license agreement with The Ohio State
University, through the Ohio State Innovation Foundation, to develop and
commercialize chimeric antigen receptor (CAR) technology targeting
multiple myeloma cells.
The CAR technology licensed to Cellectis is related to CS1, an antigen
that is over-expressed in multiple myeloma cells. Cellectis intends to
pursue the development of a CS1 CAR T-cell program for this targeted
indication.
Multiple myeloma is the second most common type of blood cancer with a
five-year survival rate of 45%. This cancer represents a major unmet
medical need.
André Choulika, Chief Executive Officer and Chairman of Cellectis stated
“This agreement aligns with our CAR T-cell development strategy to bring
innovative therapies to patients with cancer. We are pleased to have
entered into this license agreement with Ohio State University since it
is a major research center with unique and outstanding expertise in
multiple myeloma.”
Cellectis is currently developing three proprietary allogeneic CAR
T-cell product candidates in the field of liquid tumors, targeting CD123
in acute myeloid leukemia, as well as CD38 and CS1 for multiple myeloma.
Cellectis aims to file in 2015 an application for a Clinical Trial
Authorization for its allogeneic UCART191 product candidate,
which targets CD19 in acute lymphoblastic leukemia and chronic
lymphocytic leukemia.
About Cellectis
Cellectis is a gene-editing company focused on developing
immunotherapies based on gene edited engineered CAR-T cells (UCART). The
company’s mission is to develop a new generation of cancer therapies
based on engineered T-cells. Cellectis capitalizes on its 15 years of
expertise in genome engineering - based on its flagship TALEN™ products
and meganucleases and pioneering electroporation PulseAgile technology -
to create a new generation of immunotherapies. CAR technologies are
designed to target surface antigens expressed on cells. Using its
life-science-focused, pioneering genome-engineering technologies,
Cellectis’ goal is to create innovative products in multiple fields and
with various target markets. Cellectis is listed on the NYSE Alternext
market (ticker: ALCLS).
Disclaimer
This press release and the information contained herein do not
constitute an offer to sell or subscribe, or a solicitation of an offer
to buy or subscribe, for shares in Cellectis in any country. This press
release contains forward-looking statements that relate to the Company’s
objectives based on the current expectations and assumptions of the
Company’s management only and involve risk and uncertainties that could
cause the Company to fail to achieve the objectives expressed by the
forward-looking statements above.
1 Under exclusive option for Servier
Copyright Business Wire 2015